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Introduction

Results

• A complex wound is a wound that exposes functionally
important structures following debridement.
• NovoSorbTM Biodegradable Temporizing Matrix (BTM) is an
entirely synthetic matrix, made from polyurethane open-cell
foam, used in the closure of complex wounds.1
• In a complex wound, the BTM matrix is applied following
wound debridement and before split-thickness skin grafting
(STSG) to provide “dermal” structure in anticipation of the
graft. 2
Wound debridement

BTM application

Objective
To review all cases treated with
regional burn center regarding:
1. Complications of treatment
2. Success of wound closure
3. Post hospital discharge outcomes

Complex wounds
Patients
Male
Female
Age Range

37
33
20 (61%)
13 (39%)
3 months to 72
years

5%
3%
(1) (2)
22%
(8)

Exposed
structure

Locations: Head, neck, trunk, upper
arm, lower arm, hand, thigh, lower leg,
and/or foot
Causes: Burn, infection, trauma, or
amputation

70%
(26)

1

2

3

4

5

6

Figure 1. Reason for BTM application to
complex wound before STSG. The other
cases were due to a failed Integra® matrix
and an abscess.

Following
allograft
Table 2. Success of wound closure relating
removal
Failed STSG to STSG.

Success of Wound Closure*
Other

Table 1. Complications relating to the
BTM treatment in the complex wound.

BTM at the LVHN

Complex Wounds

Reason for BTM Application to Complex Wound

STSG

• Unlike other matrices, BTM does not contain biological
materials, such a collagen. Its synthetic nature makes BTM
more resistant to infection.1
• BTM has been used at the Lehigh Valley Health Network
(LVHN) regional burn center in the treatment of complex
wounds since June 2017.

NovoSorbTM

Demographics

35 (97%)

Secondary graft needed:

1 (3%)

Average:

Complications of Treatment
Reapplication of BTM
3 (8%)
(for extra dermal support):

Time between
Min:
BTM and STSG
Max:

6 (15%)

Infection of BTM:

Primary graft success:

27 days
7 days
43 days

* One patient passed away in the hospital due
to sepsis and never received STSG.

Figure 2. Photos documenting the healing process of a complex upper arm
wound. (1) Initial debridement of wound via fasciotomy. (2) Wound post VAC
and prior to BTM application. (3) BTM application to the complex wound. (4)
Wound with integrated BTM prior to STSG. (5) Thin STSG applied to wound
bed. (3) Healed complex wound 18 months post STSG.

Conclusion

Post Hospital Discharge Outcomes

Methods
• Institutional Review Board (IRB) approval and informed
consent was obtained.
• Retrospective chart review of 33 patients identified as
receiving application of BTM to a complex wound at the
LVHN burn center, from June 2017 through May 2020.
• Data collected via EPIC chart review and stored in REDCap:
– Patient demographics
– Complex wound description
– BTM data
– STSG data
– Post-op visit information
• Statistical analysis completed in Excel.

Decreased range of motion
or gait abnormalities:

12 out of 24

Contracture:

12 out of 28
(10%-80% contracture)

Reopened wounds:

12 out of 32

Patient and
Average:
Observer Scar
Assessment Min:
Scale (POSAS)
Max:
Rating

32

Average:

9

Vancouver Scar
Min:
Scale Rating
Max:

16
57

3
13

Table 3. Complex
wound outcomes
evaluated from follow
up office visits 13
days to 2.75 years
post hospital
discharge following
STSG. Not all follow
up information was
available for every
complex wound.
Information was
presented when
available.

In the past 3 years of use at the LVHN regional burn
center, BTM has proven to be a successful bridge to STSG, in
complex wounds, with a primary STSG success rate of 97%
and a low infection rate, with all infections treated locally. The
post-hospital discharge outcomes are generally good due to the
complexity of these wounds and the worse outcomes, such as
amputation, that would have preceded without the use of this
dermal matrix. Finally, BTM proved useful in both pediatric and
adult patients, as well as in use on a variety of different
locations throughout the body.
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